TheraRadar
← Back
Data updated: May 24, 2026

Teva

Generics
CardiovascularRespiratoryNeurology Execution: Needs Improvement

Teva is a generic drug manufacturer focused on Cardiovascular, Respiratory, Neurology. Key products include MICAFUNGIN.

1948
Since
769
Drugs
-
Trials
8
New Drugs (2yr)
Modality:
23 Small Molecules 1 Biologics
Novel Drugs (2016-2018):
3 Novel Approvals 1 First-in-Class 1 Orphan Drug

Teva at a Glance

  • Fast trial execution (18 months median completion)

Recent FDA Approvals

New drug approvals (NDA/BLA) in the last 2 years. Shows novel drugs only, excluding generics and label supplements.

PONLIMSI BLA
2026-03-27
denosumab-adet
DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
DAPTOMYCIN NDA
2024-11-21
daptomycin
Skin and Skin Structure Infections
BORTEZOMIB NDA
2024-08-26
bortezomib
TERIPARATIDE NDA
2024-06-04
teriparatide
Osteoporosis

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 25%
48 drugs
Respiratory 21%
14 drugs Phase 3: 32 Phase 2: 8 Phase 1: 11
Neurology 21%
25 drugs Phase 3: 18 Phase 2: 4 Phase 1: 7
Dermatology 17%
27 drugs Phase 3: 7
Oncology 16%
27 drugs Phase 3: 3 Phase 2: 1 Phase 1: 12

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

60
Phase 3
13
Phase 2
30
Phase 1

Phase 3 Readout Calendar Pro

1 Phase 3 trial with confidence-graded primary completion dates.

Full calendar →
Q4 2025
Tapinarof Cream 1%
Plaque Type Psorisis
Completed · awaiting NCT06742957

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • MICAFUNGIN leads revenue
  • • 5 key drugs tracked

Trial Catalysts

  • • Cardiovascular pipeline focus
  • • 1 Phase 3 readout tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/4 completed
  • • Speed: 18 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges